Irisin: A new potential hormonal target for the treatment of obesity and type 2 diabetes

Journal of Diabetes

Volumn 4, Issue 3, 2012, Pages 196-196

  Sanchis Gomar, Fabian ^a,b   Lippi, Giuseppe ^c   Mayero, Sara ^d   Perez Quilis, Carme ^e   García Giménez, José L ^e  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ANTIOBESITY AGENT; GW 1516; HORMONE; IRISIN; MESSENGER RNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GROWTH HORMONE; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG;

BODY WEIGHT; DISEASE ASSOCIATION; ENDURANCE TRAINING; ENERGY EXPENDITURE; EXERCISE; HUMAN; INSULIN RESISTANCE; LIFE EXPECTANCY; METABOLIC DISORDER; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; WHITE ADIPOSE TISSUE;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; EXERCISE; FIBRONECTINS; HORMONES; HUMANS; MICE; OBESITY; PHYSICAL CONDITIONING, ANIMAL;

EID: 84865314974     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2012.00194.x     Document Type: Note

References (6)

1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet. 2011; 378: 169-81.
2. Juonala M, Magnussen CG, Berenson GS et al. Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011; 365: 1876-85.
3. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 444: 840-6.
4. Bostrom P, Wu J, Jedrychowski MP et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481: 463-8.
5. Narkar VA, Downes M, Yu RT et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008; 134: 405-15.
6. Goodyear LJ. The exercise pill: Too good to be true? N Engl J Med. 2008; 23: 359.